Haemonetics Corporation (HAE) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.

Total Assets Chart for Haemonetics Corporation

Haemonetics Corporation (HAE) total assets for FY2026 were USD 2.4B, a -2.2% change from FY2025. Haemonetics Corporation's total assets grew from USD 144.8M in 1992 to USD 2.4B in 2026 (1554.6% over 34 years). Total assets compound annual growth rate: 5-year CAGR of 5.7%, 10-year CAGR of 6.2%, 20-year CAGR of 7.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$4.71B
Implied Share Price
$103.52
Enterprise Value
$5.81B
Revenue (TTM)
$1.35B
EBITDA
$358.79M
Profit Margin
7.12%
Trailing P/E
50.01
Forward P/E
20.33
Price/Book (MRQ)
5.81
Price/Sales (TTM)
3.48
EV/EBITDA
9.36
EV/Revenue
4.30
Dividend Yield
—
Book Value
$18.41
Free Cash Flow (FY2026)
$260.44M
Free Cash Flow Yield
5.53%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.